Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Protein engineering of interferon alphas.

Renqiu Hu1, Ke-Jian Lei, Joseph Bekisz

  • 1Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institute of Health, Bethesda, MD, USA.

Methods in Molecular Medicine
|July 8, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Intraperitoneal Monocytes plus IFNs as a Novel Cellular Immunotherapy for Ovarian Cancer: Mechanistic Characterization and Results from a Phase I Clinical Trial.

Clinical cancer research : an official journal of the American Association for Cancer Research·2022
Same author

Production of a cellular product consisting of monocytes stimulated with Sylatron<sup>®</sup> (Peginterferon alfa-2b) and Actimmune<sup>®</sup> (Interferon gamma-1b) for human use.

Journal of translational medicine·2019
Same author

Combination immunotherapy with IL-4 Pseudomonas exotoxin and IFN-α and IFN-γ mediate antitumor effects in vitro and in a mouse model of human ovarian cancer.

Immunotherapy·2019
Same author

A Phase 1 trial of autologous monocytes stimulated ex vivo with Sylatron<sup>®</sup> (Peginterferon alfa-2b) and Actimmune<sup>®</sup> (Interferon gamma-1b) for intra-peritoneal administration in recurrent ovarian cancer.

Journal of translational medicine·2018
Same author

<i>IRAV</i> (<i>FLJ11286</i>), an Interferon-Stimulated Gene with Antiviral Activity against Dengue Virus, Interacts with MOV10.

Journal of virology·2016
Same author

Laboratory Response to 2014 Ebola Virus Outbreak in Mali.

The Journal of infectious diseases·2016
Same journal

Methods for cancer gene therapy using tumor suppressor genes.

Methods in molecular medicine·2014
Same journal

Suppression of the human carcinoma phenotype by an antioncogene ribozyme.

Methods in molecular medicine·2014
Same journal

Methods for the use of stromal cells for therapeutic gene therapy.

Methods in molecular medicine·2014
Same journal

Methods for adenovirus-mediated gene transfer to synovium in vivo.

Methods in molecular medicine·2014
Same journal

Methods for gene transfer to synovium.

Methods in molecular medicine·2014
Same journal

Methods for generation of genetically modified fibroblasts for immunotherapy of cancer.

Methods in molecular medicine·2014
See all related articles

Engineered interferon (IFN)-alpha proteins, including hybrids and mutants, offer new insights into structure-function relationships. These modified IFNs show potential for novel therapeutic applications and enhanced clinical understanding.

Area of Science:

  • Biochemistry
  • Immunology
  • Molecular Biology

Background:

  • Interferon (IFN)-alphas are homologous proteins with high species specificity.
  • Subtle structural variations influence diverse biological actions.
  • Understanding human IFN-alpha structure-function is crucial.

Purpose of the Study:

  • To explore the utility of recombinant techniques in modifying IFN-alpha proteins.
  • To investigate the structure and function of novel IFN hybrids and mutants.
  • To assess the therapeutic potential of engineered IFNs.

Main Methods:

  • Construction and characterization of IFN-alpha hybrids and mutants using recombinant technology.
  • Expression and analysis of engineered IFN proteins.
  • Comparative studies of parental and modified IFN-alpha molecules.

Related Experiment Videos

Main Results:

  • Successful creation of the first IFN-alpha1/alpha2 hybrid in 1981.
  • Generation of numerous IFN hybrids and mutants with combined or altered biological properties.
  • Demonstration that engineered IFNs serve as powerful tools for structure-function studies.

Conclusions:

  • IFN hybrids and mutants are valuable for dissecting IFN-alpha structure-function relationships.
  • Engineered IFNs hold promise for new therapeutic strategies.
  • Further research into engineered IFNs can deepen the understanding of their clinical activities.